Oncology

In light of the CTN clearance, Interius expects to initiate plans for a phase 1 clinical trial (INVISE) for INT2104 within the final quarter of 2024.

Review top news and interview highlights from the week ending July 12, 2024.

GT Biopharma anticipates initiating the phase 1 clinical trial in the second half of 2024.

The PhD candidate from Lieden University Medical Center and Breakefield Lab at Mass Gen discussed her work presented at the ASGCT 2024 meeting.

The associate professor of medicine at University of Colorado discussed how the field has shifted to support the growing use of CAR Ts and progress to come.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

The Prescription Drug User Fee Act (PDUFA) target action date is August 4, 2024.

Review top news and interview highlights from the week ending July 5, 2024.

The associate professor of medicine at University of Colorado discussed a post hoc analysis study on subgroup analyses of liso-cel response.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Patients in FUMANBA-2 received eque-cel after being ineligible for ASCT after 4 cycles of induction therapy.

Eight patients receiving either TSC-100 or TSC-101 have been disease-free for a median of 10 months of follow-up.

Review top news and interview highlights from the week ending June 28, 2024.

Notably, 1 patient treated in the trial died of respiratory failure, but it is not clear whether the death was related to LYL797.

The associate professor of medicine at University of Colorado discussed data in the primary relapsed LBCL setting.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The company has dosed the sixth patient in the study, and expects to move onto the third cohort pending continued safety at 1 month posttreatment.

The professor from Cedars Sinai discussed further research being conducted in the field after lifileucel’s approval.

With the company having recently announced that it intends to expand the clinical trial with a new cohort, CGTLive® has decided to take a closer look at this ongoing study.

Review top news and interview highlights from the week ending June 21, 2024.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The responses seen in the 9 patients included 3 complete responses (CRs), 2 very good partial responses, and 4 partial responses.

In terms of safety, SNK02 was characterized as “well-tolerated”.

Earlier and prophylactic interventions have enabled low rates and severity of AEs in recent years of administration.